Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Avoiding Drug Resistance in HIV Reverse Transcriptase
Maria E. Cilento, Karen A. Kirby, Stefan G. Sarafianos
Chemical Reviews (2021) Vol. 121, Iss. 6, pp. 3271-3296
Open Access | Times Cited: 68

Showing 1-25 of 68 citing articles:

Recent advances in carbon quantum dots for virus detection, as well as inhibition and treatment of viral infection
Yuxiang Xue, Chenchen Liu, Gavin Andrews, et al.
Nano Convergence (2022) Vol. 9, Iss. 1
Open Access | Times Cited: 74
Recent Advances in Pyrimidine-Based Drugs
Baskar Nammalwar, Richard A. Bunce
Pharmaceuticals (2024) Vol. 17, Iss. 1, pp. 104-104
Open Access | Times Cited: 40
Target-based drug design strategies to overcome resistance to antiviral agents: opportunities and challenges
Shaoqing Du, Xueping Hu, Luis Menéndez‐Arias, et al.
Drug Resistance Updates (2024) Vol. 73, pp. 101053-101053
Closed Access | Times Cited: 18
Approved HIV reverse transcriptase inhibitors in the past decade
Guangdi Li, Yali Wang, Erik De Clercq
Acta Pharmaceutica Sinica B (2021) Vol. 12, Iss. 4, pp. 1567-1590
Open Access | Times Cited: 77
Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors
Zhao Wang, Srinivasulu Cherukupalli, Minghui Xie, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 5, pp. 3729-3757
Open Access | Times Cited: 50
A Review of FDA-Approved Anti-HIV-1 Drugs, Anti-Gag Compounds, and Potential Strategies for HIV-1 Eradication
Belgin Sever, Masami Otsuka, Mikako Fujita, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3659-3659
Open Access | Times Cited: 13
Insights into HIV-1 Reverse Transcriptase (RT) Inhibition and Drug Resistance from Thirty Years of Structural Studies
Abhimanyu K. Singh, Kalyan Das
Viruses (2022) Vol. 14, Iss. 5, pp. 1027-1027
Open Access | Times Cited: 32
HIV nucleoside reverse transcriptase inhibitors
Franck Amblard, Dharmeshkumar Patel, Eleftherios Michailidis, et al.
European Journal of Medicinal Chemistry (2022) Vol. 240, pp. 114554-114554
Open Access | Times Cited: 32
HIV drug resistance in the era of contemporary antiretroviral therapy: A clinical perspective
Andrew Carr, Nicola Mackie, Roger Paredes, et al.
Antiviral Therapy (2023) Vol. 28, Iss. 5
Open Access | Times Cited: 21
Structure-Based Optimization of 2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: Exploiting the Tolerant Regions of the Non-Nucleoside Reverse Transcriptase Inhibitors’ Binding Pocket
Fabao Zhao, Heng Zhang, Minghui Xie, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 3, pp. 2102-2115
Closed Access | Times Cited: 18
A Review on FDA Approved Anti-HIV-1 Drugs, Anti-Gag Compounds and Potential Strategies for HIV-1 Eradication
Belgin Sever, Masami Otsuka, Mikako Fujita, et al.
(2024)
Open Access | Times Cited: 6
Pharmacological advances in anti‐retroviral therapy for human immunodeficiency virus‐1 infection: A comprehensive review
Nursyuhada Azzman, Muhammad Shoaib Ali Gill, Sharifah Syed Hassan, et al.
Reviews in Medical Virology (2024) Vol. 34, Iss. 2
Open Access | Times Cited: 6
Deciphering the enigmas of non‐nucleoside reverse transcriptase inhibitors (NNRTIs): A medicinal chemistry expedition towards combating HIV drug resistance
Kun Zhang, Yujie Zhang, Min Li, et al.
Medicinal Research Reviews (2024)
Closed Access | Times Cited: 6
2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 NNRTIs: Rational Design, Synthesis, Activity Evaluation, and Crystallographic Studies
Dongwei Kang, Francesc X. Ruiz, Yanying Sun, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 7, pp. 4239-4256
Open Access | Times Cited: 40
Why the HIV Reservoir Never Runs Dry: Clonal Expansion and the Characteristics of HIV-Infected Cells Challenge Strategies to Cure and Control HIV Infection
Chuen‐Yen Lau, Matthew A. Adan, Frank Maldarelli
Viruses (2021) Vol. 13, Iss. 12, pp. 2512-2512
Open Access | Times Cited: 33
Drug Resistance: An Incessant Fight against Evolutionary Strategies of Survival
Francisco Ramos‐Martín, Nicola D’Amelio
Microbiology Research (2023) Vol. 14, Iss. 2, pp. 507-542
Open Access | Times Cited: 14
Discovery of diarylpyrimidine derivatives bearing piperazine sulfonyl as potent HIV-1 nonnucleoside reverse transcriptase inhibitors
Xiangyi Jiang, Boshi Huang, Shawn Rumrill, et al.
Communications Chemistry (2023) Vol. 6, Iss. 1
Open Access | Times Cited: 14
Structure‐based design of diarylpyrimidines and triarylpyrimidines as potent HIV‐1 NNRTIs with improved metabolic stability and drug resistance profiles
Minghui Xie, Zhao Wang, Fabao Zhao, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 3
Closed Access | Times Cited: 5
In situ click chemistry-based discovery of 1,2,3-triazole-derived diarylpyrimidines as novel HIV-1 NNRTIs by exploiting the tolerant region I in binding pocket
Yanying Sun, Da Feng, Zhenzhen Zhou, et al.
Bioorganic & Medicinal Chemistry (2023) Vol. 96, pp. 117484-117484
Closed Access | Times Cited: 11
Nanoparticle‑based antiviral strategies to combat the influenza virus (Review)
Clara Patricia Ríos-Ibarra, Mauricio Salinas‐Santander, Danielle A. Orozco‐Nunnelly, et al.
Biomedical Reports (2024) Vol. 20, Iss. 4
Open Access | Times Cited: 4
Discovery of novel sulfonamide substituted indolylarylsulfones as potent HIV-1 inhibitors with better safety profiles
Shenghua Gao, Letian Song, Yusen Cheng, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 6, pp. 2747-2764
Open Access | Times Cited: 10
Escaping from Flatland: Multiparameter Optimization Leads to the Discovery of Novel Tetrahydropyrido[4,3-d]pyrimidine Derivatives as Human Immunodeficiency Virus-1 Non-nucleoside Reverse Transcriptase Inhibitors with Superior Antiviral Activities against Non-nucleoside Reverse Transcriptase Inhibitor-Resistant Variants and Favorable Drug-like Profiles
Zhao Wang, Prem P. Sharma, Brijesh Rathi, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 13, pp. 8643-8665
Closed Access | Times Cited: 10
State of the ART (antiretroviral therapy): Long-acting HIV-1 therapeutics
S Ravichandran, William M. McFadden, Alexa A. Snyder, et al.
Global Health & Medicine (2024)
Closed Access | Times Cited: 3
Single-cell delineation of strain-specific HIV-1 Vif activities using dual reporter sensor cells and live cell imaging
Jorge F. Guerrero, Laraine L. Zimdars, James W. Bruce, et al.
Journal of Virology (2025)
Open Access
Considerations for capsid-targeting antiretrovirals in pre-exposure prophylaxis
William M. McFadden, Mia Færch, Karen A. Kirby, et al.
Trends in Molecular Medicine (2025)
Closed Access
Page 1 - Next Page

Scroll to top